The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2019 | CD19 CAR T-cell therapy for lymphoma
Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany discusses CD19 CAR T-cell therapy against acute- and non-Hodgkin lymphoma. Being the 4th trial of its kind worldwide, Prof. Schmitt examines the need for new technology therapies to prevent patient relapse. This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.
